The EBMT risk score

被引:241
作者
Gratwohl, A. [1 ]
机构
[1] Univ Basel Hosp, CH-4053 Basel, Switzerland
关键词
hematopoietic SCT; autologous; allogeneic; risk assessment; EBMT risk score; STEM-CELL TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; VERSUS-HOST-DISEASE; UNRELATED DONORS; H-Y; IMPACT; CYTOMEGALOVIRUS; VALIDATION;
D O I
10.1038/bmt.2011.110
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The European Group for Blood and Marrow Transplantation (EBMT) risk score provides a simple tool to assess instantly chances and risks of hematopoietic SCT(HSCT) for an individual patient pre-transplant. Five factors, age of the patient, stage of the disease, time from diagnosis, donor type and donor recipient gender combination augment risk for an individual patient with increasing score from 0 as best to 7 as worst in an additive way. The score holds for all acquired hematological disorders, for allogeneic and autologous HSCT (score 0-5), is independent of the HSCT technology and is valid for standard or reduced intensity conditioning. Survival is uniformly worse for older patients, transplanted in advanced disease stage after a long-time interval and with a mismatched donor than for younger patients, transplanted soon in early stage with a well matched donor. Additional risk factors such as performance score, CMV serostatus or cytokine polymorphisms improve prediction but to different extents for low or high-risk patients. Comparative assessment of disease risk and global pre-transplant risk should guide decisions for each patient with his/her specific disease between HSCT and a non-transplant approach and replace the traditional 'donor vs no donor' with such a risk-adapted individualized strategy. Bone Marrow Transplantation (2012) 47, 749-756; doi:10.1038/bmt.2011.110; published online 6 June 2011
引用
收藏
页码:749 / 756
页数:8
相关论文
共 43 条
[1]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[2]   Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].
Cassileth, PA ;
Harrington, DP ;
Appelbaum, FR ;
Lazarus, HM ;
Rowe, JM ;
Paietta, E ;
Willman, C ;
Hurd, DD ;
Bennett, JM ;
Blume, KG ;
Head, DR ;
Wiernik, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656
[3]   Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland [J].
Chalandon, Y ;
Tiercy, JM ;
Schanz, U ;
Gungor, T ;
Seger, R ;
Halter, J ;
Helg, C ;
Chapuis, B ;
Gratwohl, A ;
Tichelli, A ;
de Faveri, GN ;
Roosnek, E ;
Passweg, J .
BONE MARROW TRANSPLANTATION, 2006, 37 (10) :909-916
[4]   Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis [J].
Craddock, C ;
Szydlo, RM ;
Dazzi, F ;
Olavarria, E ;
Cwynarski, K ;
Yong, A ;
Brookes, P ;
de la Fuente, J ;
Kanfer, E ;
Apperley, JF ;
Goldman, JM .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) :228-236
[5]   Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT [J].
Crawley, C ;
Szydlo, R ;
Lalancette, M ;
Bacigalupo, A ;
Lange, A ;
Brune, M ;
Juliusson, G ;
Nagler, A ;
Gratwohl, A ;
Passweg, J ;
Komarnicki, M ;
Vitek, A ;
Mayer, J ;
Zander, A ;
Sierra, J ;
Rambaldi, A ;
Ringden, O ;
Niederwieser, D ;
Apperley, JF .
BLOOD, 2005, 106 (09) :2969-2976
[6]   HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry [J].
Crocchiolo, R. ;
Ciceri, F. ;
Fleischhauer, K. ;
Oneto, R. ;
Bruno, B. ;
Pollichieni, S. ;
Sacchi, N. ;
Sormani, M. P. ;
Fanin, R. ;
Bandini, G. ;
Bonifazi, F. ;
Bosi, A. ;
Rambaldi, A. ;
Alessandrino, P. E. ;
Falda, M. ;
Bacigalupo, A. .
BONE MARROW TRANSPLANTATION, 2009, 44 (09) :571-577
[7]  
de Souza CA, 2005, HAEMATOLOGICA, V90, P232
[8]   Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure [J].
Duval, Michel ;
Klein, John P. ;
He, Wensheng ;
Cahn, Jean-Yves ;
Cairo, Mitchell ;
Camitta, Bruce M. ;
Kamble, Rammurti ;
Copelan, Edward ;
de Lima, Marcos ;
Gupta, Vikas ;
Keating, Armand ;
Lazarus, Hillard M. ;
Litzow, Mark R. ;
Marks, David I. ;
Maziarz, Richard T. ;
Rizzieri, David A. ;
Schiller, Gary ;
Schultz, Kirk R. ;
Tallman, Martin S. ;
Weisdorf, Daniel .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) :3730-3738
[9]   Risk assessment in haematopoietic stem cell transplantation: Impact of donor-recipient sex combination in allogeneic transplantation [J].
Gahrton, Gosta .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (02) :219-229
[10]   Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. [J].
Gooley, Ted A. ;
Chien, Jason W. ;
Pergam, Steven A. ;
Hingorani, Sangeeta ;
Sorror, Mohamed L. ;
Boeckh, Michael ;
Martin, Paul J. ;
Sandmaier, Brenda M. ;
Marr, Kieren A. ;
Appelbaum, Frederick R. ;
Storb, Rainer ;
McDonald, George B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (22) :2091-2101